The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Current status and future directions of cancer immunotherapy
Open accessAbstract
In the past decades, our knowledge about the relationship between cancer and the immune system has increased considerably. Recent years' success of cancer immunotherapy including monoclonal antibodies (mAbs), cancer vaccines, adoptive cancer therapy and the immune checkpoint therapy has revolutionized traditional cancer treatment. However, challenges still exist in this field. Personalized combination therapies via new techniques will be the next promising strategies for the future cancer treatment direction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Clinical and Experimental Immunology
Kay, H. (1966) · PubMed Central · Cited by 2,177
Advances in Experimental Medicine and Biology
Lunt, G. G. (1986) · Neurochemistry International · doi:10.1016/0197-0186(86)90020-3 · Cited by 1,851
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Genin, M., Clement, F., Fattaccioli, A., Raes, M., & Michiels, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1546-9 · Cited by 1,090
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Current Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Human Vaccines & Immunotherapeutics: News
Riedmann, E. M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26189 · Cited by 462
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Humoral immunity, inflammation and cancer
Tan, T.-T., & Coussens, L. M. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.001 · Cited by 417
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
Chouaib, S., Noman, M. Z., Kosmatopoulos, K., & Curran, M. A. (2017) · Oncogene · doi:10.1038/onc.2016.225 · Cited by 365
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
B Cells and Humoral Immunity in Atherosclerosis
Tsiantoulas, D., Diehl, C. J., Witztum, J. L., & Binder, C. J. (2014) · Circulation Research · doi:10.1161/circresaha.113.301145 · Cited by 296
Translational Andrology and Urology
(2026) · Translational Andrology and Urology · doi:10.21037/tau · Cited by 290
Macrophages, Inflammation, and Lung Cancer
Conway, E. M., Pikor, L. A., Kung, S. H. Y., Hamilton, M. J., Lam, S., Lam, W. L., & Bennewith, K. L. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1545ci · Cited by 286
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 285
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252
Treating cancer with genetically engineered T cells
Park, T. S., Rosenberg, S. A., & Morgan, R. A. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.04.009 · Cited by 218
Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 213
Gül, N., & van Egmond, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1330 · Cited by 210
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Becker, P. S. A., Suck, G., Nowakowska, P., Ullrich, E., Seifried, E., Bader, P., Tonn, T., & Seidl, C. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1792-y · Cited by 208
Immune system: a double-edged sword in cancer
Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., & Ramakrishna, S. (2013) · Inflammation Research · doi:10.1007/s00011-013-0645-9 · Cited by 206
Cancer and Innate Immune System Interactions: Translational Potentials for Cancer Immunotherapy
Liu, Y., & Zeng, G. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182518e83 · Cited by 185
Barbee, M. S., Ogunniyi, A., Horvat, T. Z., & Dang, T.-O. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015586218 · Cited by 179
Functions of Heat Shock Proteins in Pathways of the Innate and Adaptive Immune System
Binder, R. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401417 · Cited by 175
Benzon, B., Zhao, S. G., Haffner, M. C., Takhar, M., Erho, N., Yousefi, K., Hurley, P., Bishop, J. L., Tosoian, J., Ghabili, K., et al. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.49 · Cited by 170
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 160
Epigenetic cancer therapy: rationales, targets and drugs
Rius, M., & Lyko, F. (2012) · Oncogene · doi:10.1038/onc.2011.601 · Cited by 157 · cited 1×
“For decades, the conventional anticancer treatment strategies have been surgery, chemotherapy, and radiotherapy [1, 2].”
BackgroundCombination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 143
Guillerme, J.-B., Boisgerault, N., Roulois, D., Ménager, J., Combredet, C., Tangy, F., Fonteneau, J., & Grégoire, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2733 · Cited by 142
Kono, K., Iinuma, H., Akutsu, Y., Tanaka, H., Hayashi, N., Uchikado, Y., Noguchi, T., Fujii, H., Okinaka, K., Fukushima, R., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-141 · Cited by 141
Borghaei, H., Smith, M. R., & Campbell, K. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.067 · Cited by 138
Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 135
Chemotherapy and immunotherapy: mapping the road ahead
Cook, A., Lesterhuis, W. J., Nowak, A. K., & Lake, R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.003 · Cited by 135
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 115
Combinatorial immunotherapy and nanoparticle mediated hyperthermia
Moy, A. J., & Tunnell, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.008 · Cited by 114
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
Haabeth, O. A. W., Lorvik, K. B., Yagita∥, H., Bogen, B., & Corthay, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1039763 · Cited by 113
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 110
The use of combinations of monoclonal antibodies in clinical oncology
Henricks, L. M., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.10.008 · Cited by 106
Advances in personalized cancer immunotherapy
Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2016) · Breast Cancer · doi:10.1007/s12282-016-0688-1 · Cited by 105
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 105
Hide-and-seek: the interplay between cancer stem cells and the immune system
Sultan, M., Coyle, K. M., Vidovic, D., Thomas, M. L., Gujar, S. A., & Marcato, P. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw115 · Cited by 98
Overcoming Antigen Escape with CAR T-cell Therapy
Jackson, H. J., & Brentjens, R. J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1275 · Cited by 96
Eosinophils: important players in humoral immunity
Berek, C. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12695 · Cited by 91
Immunotherapy approaches in the treatment of malignant brain tumors
Dunn‐Pirio, A., & Vlahovic, G. (2016) · Cancer · doi:10.1002/cncr.30371 · Cited by 91
Gene-expression profiling to predict responsiveness to immunotherapy
Jamieson, N. B., & Maker, A. V. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.63 · Cited by 91
Trends and advances in tumor immunology and lung cancer immunotherapy
Aldarouish, M., & Wang, C. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0439-3 · Cited by 87
Advances in cancer immunology and cancer immunotherapy.
Voena, C., & Chiarle, R. (2016) · PubMed · Cited by 85
Cancer Immunology and Immunotherapy
Sukari, A. W., Nagasaka, M., Al‐Hadidi, A., & Lum, L. G. (2016) · Anticancer Research · doi:10.21873/anticanres.11144 · Cited by 82
Ning, C., Xie, B., Zhang, L., Li, C., Shan, W., Yang, B., Luo, X., Gu, C., He, Q., Jin, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1260 · Cited by 80
Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective
Hawkins, R. E., Gilham, D. E., Debets, R., Eshhar, Z., Taylor, N. N., Abken, H., Schumacher, T. N., & ATTACK Consortium (2010) · Human Gene Therapy · doi:10.1089/hum.2010.086 · Cited by 79
Translational research : the journal of laboratory and clinical medicine.
ScienceDirect (2006) · Cited by 78
Recent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 77
Radiolabeled Antibodies for Cancer Imaging and Therapy
Barbet, J., Bardiès, M., Bourgeois, M., Chatal, J., Chérel, M., Davodeau, F., Faivre-Chauvet, A., Gestin, J., & Kraeber‐Bodéré, F. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-974-7_38 · Cited by 76
Burnet, F. M., & Fenner, F. J. (1948) · Heredity · doi:10.1038/hdy.1948.19 · Cited by 70
Twardowski, P. W., Kanaya, N., Frankel, P. H., Synold, T. W., Ruel, C., Pal, S. K., Junqueira, M., Prajapati, M., Moore, T., Tryon, P., et al. (2015) · Cancer · doi:10.1002/cncr.29421 · Cited by 69
Buie, L. W., Pecoraro, J. J., Horvat, T. Z., & Daley, R. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015588555 · Cited by 67
Wang, J., Su, X., Liu, Y., Qiao, F., Yu, F., Yu, L., Yang, Q., Wang, Y., Yin, Y., Chen, R., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.29998 · Cited by 67
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
Ciccarese, C., Alfieri, S., Santoni, M., Santini, D., Brunelli, M., Bergamini, C., Licitra, L. F., Montironi, R., Tortora, G., & Massari, F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1120287 · Cited by 66
Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
Ishihara, D., Pop, L. M., Takeshima, T., Iyengar, P., & Hannan, R. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1914-6 · Cited by 65
Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy
Liu, L., Sommermeyer, D., Cabanov, A., Kosasih, P. L., Hill, T. J., & Riddell, S. R. (2016) · Nature Biotechnology · doi:10.1038/nbt.3461 · Cited by 63
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 61
Bielinska, A. U., Makidon, P. E., Janczak, K. W., Blanco, L. P., Swanson, B. J., Smith, D. M., Pham, T., Szabó, Z., Kukowska‐Latallo, J. F., & Baker, J. R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301424 · Cited by 57
Epigenetic Modulators and the New Immunotherapies
Dear, A. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1514673 · Cited by 57
Salimu, J., Spary, L. K., Al‐Taei, S., Clayton, A., Mason, M. D., Staffurth, J. N., & Tabi, Z. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0079 · Cited by 53
Bioinformatics for cancer immunology and immunotherapy
Charoentong, P., Angelova, M., Efremova, M., Gallasch, R., Hackl, H., Galon, J., & Trajanoski, Z. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1354-x · Cited by 52
Hanlon, D. J., Aldo, P. B., Devine, L., et al. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00968.x · Cited by 51
Physician Attitudes toward Adult Vaccines and other Preventive Practices, United States, 2012
Hurley, L. P., Bridges, C. B., Harpaz, R., Allison, M. A., Leary, S. T. O., Crane, L. A., Brtnikova, M., Stokley, S. K., Beaty, B. L., Jimenez-Zambrano, A. M., et al. (2016) · Public Health Reports · doi:10.1177/003335491613100216 · Cited by 51
A primer on precision medicine informatics
Sboner, A., & Elemento, O. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv032 · Cited by 50
From Whole Monoclonal Antibodies to Single Domain Antibodies: Think Small
Teillaud, J. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_1 · Cited by 49
Zhou, L., Wang, K., Li, Q., Nice, E. C., Zhang, H., & Huang, C. (2016) · Expert Review of Proteomics · doi:10.1586/14789450.2016.1159959 · Cited by 49
Self-citationCancer vaccine: learning lessons from immune checkpoint inhibitors
Ye, Z., Qian, Q., Jin, H., & Qian, Q. (2017) · Journal of Cancer · doi:10.7150/jca.20059 · Cited by 47
Abdel-Rahman, O., & Fouad, M. (2016) · Immunotherapy · doi:10.2217/imt-2015-0020 · Cited by 46
Systems immune monitoring in cancer therapy
Greenplate, A. R., Johnson, D. B., Ferrell, P. B., & Irish, J. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.085 · Cited by 46
Tavaré, R., Sagoo, P., Varama, G., Tanriver, Y., Warely, A., Diebold, S. S., Southworth, R., Schaeffter, T., Lechler, R. I., Razavi, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019662 · Cited by 43
CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells
Zhu, Z., Cuss, S. M., Singh, V., Gurusamy, D., Shoe, J. L., Leighty, R. M., Bronte, V., & Hurwitz, A. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401571 · Cited by 42
Molecular imaging of cell-mediated cancer immunotherapy
Lucignani, G., Ottobrini, L., Martelli, C., Rescigno, M., & Clerici, M. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.07.003 · Cited by 41
Future prospects of monoclonal antibodies as magic bullets in Immunotherapy
Maleki, L. A., Baradaran, B., Majidi, J., Mohammadian, M., & Shahneh, F. Z. (2013) · Human Antibodies · doi:10.3233/hab-130266 · Cited by 39
Blinatumomab for the treatment of B-cell lymphoma
Oak, E., & Bartlett, N. L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1021415 · Cited by 39
Podack, E. R., & Munson, G. P. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00464 · Cited by 39
Schmitt, T. M., Stromnes, I. M., Chapuis, A. G., & Greenberg, P. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0860 · Cited by 38
Advances in the understanding of cancer immunotherapy
Shore, N. D. (2014) · British Journal of Urology · doi:10.1111/bju.12692 · Cited by 37
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
Schvartsman, G., Ferrarotto, R., & Massarelli, E. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016661164 · Cited by 36
Chimeric antigen receptor modified T cell therapy for B cell malignancies
Turtle, C. J. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1490-x · Cited by 35
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Jung, C. Y., & Antonia, S. J. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.0120 · Cited by 35
Accolla, R. S., & Tosi, G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-154 · Cited by 34
Ponte, J. F., Ponath, P. D., Gulati, R., Slavonic, M., Paglia, M., O’Shea, A., Tone, M., Waldmann, H., Vaickus, L., & Rosenzweig, M. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03228.x · Cited by 29
Genomic determinants of cancer immunotherapy
Miao, D., & Allen, E. M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.010 · Cited by 29
Bioinformatics for cancer immunotherapy target discovery
Olsen, L. R., Campos, B., Barnkob, M. B., Winther, O., Brusić, V., & Andersen, M. H. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1627-7 · Cited by 28
Brehm, C., Huenecke, S., Esser, R., Kloeß, S., Quaiser, A., Betz, S., Zimmermann, O. L., Soerensen, J., Passweg, J. R., Klingebiel, T. E., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1556-5 · Cited by 28
Personalized cancer immunotherapy using Systems Medicine approaches
Gupta, S. K., Jaitly, T., Schmitz, U., Schuler, G., Wolkenhauer, O., & Vera, J. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv046 · Cited by 27
In vivo imaging of therapy-induced anti-cancer immune responses in humans
Aarntzen, E. H. J. G., Srinivas, M., Radu, C. G., Punt, C. J. A., Boerman, O. C., Figdor, C. G., Oyen, W. J. G., & de Vries, I. J. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1159-2 · Cited by 26
New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer
Thill, M. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.993318 · Cited by 24
Stone, J. D., Chervin, A. S., Aggen, D. H., & Kranz, D. M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00008-2 · Cited by 24
Chemotherapy and immunotherapy: A close interplay to fight cancer?
Hanoteau, A., & Moser, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1190061 · Cited by 22
T cell-based gene therapy of cancer
Gill, S. I., & Kalos, M. D. (2012) · Translational research · doi:10.1016/j.trsl.2012.11.002 · Cited by 21
Immune checkpoint inhibitors: a new frontier in bladder cancer
Kates, M. R., Sopko, N. A., Matsui, H., Drake, C. G., Hahn, N. M., & Bivalacqua, T. J. (2015) · World Journal of Urology · doi:10.1007/s00345-015-1709-y · Cited by 20
Kusabuka, H., Fujiwara, K., Tokunaga, Y., Hirobe, S., Nakagawa, S., & Okada, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.054 · Cited by 20
Dustin, M. L. (2016) · Nature · doi:10.1038/nature17310 · Cited by 17
Ye, Z., Li, Z., Jin, H., & Qian, Q. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_3 · Cited by 17
Adusumilli, P. S., Cha, E., Cornfeld, M. J., Davis, T. A., Diab, A. K., Dubensky, T. W., Evans, E. E., Grogan, J. L., Irving, B. A., Leidner, R. S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0253-2 · Cited by 17
Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective
Bernicker, E. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0287-sa · Cited by 14
Challenges in the implementation of trastuzumab biosimilars
Pivot, X. B., Aulagner, G., Blay, J., Fumoleau, P., Kaliski, A., Sarkozy, F., & Limat, S. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000287 · Cited by 13
Cancer immunotherapy drives implementation science in oncology
Speiser, D. E., & Flatz, L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.983000 · Cited by 11
Immunotherapy-based combinations: current status and perspectives
Miguel, M. J. D., Mansinho, A., Boni, V., & Calvo, E. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000391 · Cited by 10
Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh, S., Marabelle, A., Soria, J., & Armand, J. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.12.06 · Cited by 8
Cancer Immunotherapy using Tumor Antigen-Reactive T Cells
Choi, B. K., Kim, S.-H., Kim, Y. H., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0130 · Cited by 8
Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy.
Hatae, R., & Chamoto, K. (2016) · PubMed · doi:10.11406/rinketsu.57.2224 · Cited by 7
Current markers and their value in the era of immuno-oncology
von Rundstedt, F.-C., & Necchi, A. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.11.11 · Cited by 6
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Mattiuzzi, C., & Lippi, G. (2019) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.191008.001 · Cited by 1,491
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Engineering microrobots for targeted cancer therapies from a medical perspective
Schmidt, C. K., Medina-Sánchez, M., Edmondson, R. J., & Schmidt, O. G. (2020) · Nature Communications · doi:10.1038/s41467-020-19322-7 · Cited by 441
A deep learning genome-mining strategy for biosynthetic gene cluster prediction
Hannigan, G. D., Prihoda, D., Palicka, A., Soukup, J., Klempir, O., Rampula, L., Durcak, J., Wurst, M., Kotowski, J., Chang, D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz654 · Cited by 413
Metadata
- Authors
- Zhang, H., & Chen, J.
- Venue
- Journal of Cancer
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 9
- Issue
- 10
- Pages
- 1773-1781
- ISSN
- 1837-9664 (ISSN-L)
- OpenAlex
- W2801248003
- Cited by
- 345
- References
- 126
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.